Wealth Enhancement Trust Services’s Lucid Diagnostics LUCD Stock Holding History

Wealth Enhancement Trust Services’s Portfolio LUCD Stock Details LUCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26	Buy	+24	New	+$26	﹤0.01%	1490

Other funds holding LUCD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return

XML Financial Bethesda, Maryland $1.37B AUM 28.49% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wealth Enhancement Trust Services's LUCD Position: Q2 2026 in Review

Wealth Enhancement Trust Services opened a new position in Lucid Diagnostics (LUCD) in Q2 2026: 24 shares worth $26. The stake represents ﹤0.01% of the portfolio and ranks #1490 among its holdings.

70 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

Wealth Enhancement Trust Services held 24 shares of Lucid Diagnostics worth $26 as of Q2 2026.
Lucid Diagnostics was a new Wealth Enhancement Trust Services position in Q2 2026.
Lucid Diagnostics made up ﹤0.01% of Wealth Enhancement Trust Services's portfolio in Q2 2026, its #1490 holding.
70 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q2 2026, filed 15 Jul 2026.